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Summary: A simple, continuous Spectrophotometric method for the determination of tissue monoamine
oxidase based on the oxidation of 2,2'-azino-di-(3-ethylbenzthiazoline-6-sulphonate) (ABTS) using peroxidase
has already been described (Ivanovic, I. & Majkic-Singh, N. (1986) Fresenius Z. Anal. Chem. 324, 307). In
the present study the method is optimised for platelet monoamine oxidase assay and applied to healthy
persons and schizophrenic patients. The obtained data were statistically analysed. The continuous ABTS
method is sensitive, precise (CV below 6.9%) and linear up to 83 U/g protein. Comparison with the end-
point method of Szutowicz et al. (1984) Anal. Biochem. 138, 86 — 94)) gave a good correlation (r = 0.983).
The reference values for the activity of human platelet monoamine oxidase by the new continuous ABTS
method are 25 to 42 U/g protein (x = 33.2 U/g protein, CV = 15.5%, n = 67). No differences were found
between females and males, or between three age groups ranging from 21 to 52 years. The patients with
chronic (n = 76) or acute (n = 17) schizophrenia had significantly lower monoamine oxidase activities com-
pared with normal values (p < 0.005), which indicates that platelet monoamine oxidase can be a possible
marker for schizophrenic diseases.
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Suzutowicz et al. (8) used the same chromogen for an
end-point monoamine oxidase assay. The ABTS
method, proposed here, based on the measurement of
the initial reaction rate, is simpler and faster than the
previously described end-point method (8). This con-
tinuous monitoring method was applied to platelets
and statistically evaluated. Reference values were de-
termined, and the method was applied to platelet
samples obtained from schizophrenic patients.
Statistical methods
Statistical parameters, such as the mean value (x), standard
deviation (SD), coefficient of variation (CV) and Student's t-
test were calculated with standard statistical methods. Our
method was compared with the end-poin{ method (8) by regres-
sion analysis using the method of least squares (12).
Apparatus
All spectrophotometric measurements were performed with
Beckman DU-8 and Gilford Stasar-III spectrophotometers.
Materials and Methods
Chemicals
The diammonium salt of 2,2'-azino-di(3-ethylbenzthiazoline-6-
sulphonate) cryst., was purchased from Boehringer Mannheim,
FRG. Horseradish peroxidase, with specific activity 250 kU
• g"1, benzylamine hydrochloride, tyramine free base, harmaline
hydrochloride, pargiline hydrochloride and all other chemicals
of analytical reagent grade were obtained from Sigma Chemical
Co. USA.
Biological materials
The investigations were carried out on human platelets prepared
according to Zeller et al. (9). The platelet samples were kept at
— 70 °C before determination of the monoamine oxidase cata-
lytic activity. The monoamine oxidase was quantitatively iso-
lated from platelets according to Summers et al. (10). The
obtained platelet homogenate suspension was used for all ex-
periments.
The control group contained 67 apparently healthy persons of
both sexes between 21 and 52 years of age. The 93 males and
females between 17 and 62 years of age were separated into
two subgroups of chronic and acute illness with confirmed
diagnosis. The first group consisted of 76 subjects and the
second one of 17 patients. No therapy with monoamine oxidase
inhibitors was applied.
Reagent solution
The optimal concentration of each component of the reagent
was determined. The reagent had the following composition:
0.5 mmol benzylamine or 1.0 mmol tyramine, 2.0 mmol ABTS,
2000 U peroxidase and 30 mmol NaN3 in 1000 ml of· 100 mmol/1
TRIS-HC1 buffer, pH 7.6.
Spectrophotometric assay of monoamine oxidase
Procedure
Pipette into the cuvette 1.0 ml of reagent solution and 10 μΐ of
platelet homogenate suspension, mix well and equilibrate for 5
minutes at 37 °C. The increase of absorbance at 410 nm in a
1.0 cm light path is recorded after 1, 2 and 3 minutes imme-
diately following the preincubation. Absorbance changes per
minute (AA^onm/min) are calculated.
Calculation
The monoamine oxidase activity was calculated as AA4,0nm/niin
χ 3961 on the basis of an ABTS molar lineic absorbance of
2550 m2/mol (6), Monoamine oxidase activity was expressed as
units per gram of protein. Protein was determined according
to Lowry et al. (11).
Results
Continuous monitoring assay of monoamine
oxidase
The new spectrophotometric, continuous monitoring
method for determination of monoamine oxidase cat-
alytic activity in tissue, based on oxidation of the
chromogen ABTS through the system of coupled re-
actions catalysed by monoamine oxidase and perox-
idase, has already been published (7). To optimise this
assay for estimation of platelet monoamine oxidase
activity, the conditions characterising this reaction
system were studied. The optimal concentrations of
benzylamine and tyramine as substrates were deter-
mined by varying their concentrations over the ranges
0 — 1.0 mmol/1. Measurements were made with 78 U/g
protein monoamine oxidase, using a reagent solution
containing 2 mmol/1 ABTS and 2000 U/l peroxidase
in 100 mmol/1 TRIS-HC1 buffer, pH 7.6. All deter-
minations were done in triplicate. The resulting Li-
neweaver-Burk plots gave Km = 0.204 mmol/1 for
benzylamine and 0.284 mmol/1 for tyramine (fig. 1).
The maximum velocity for both substrates was ob-
tained with 2.0 mmol/1 ABTS and 2000 U/l peroxi-
dase, using 0.5 mmol/1 benzylamine or 1.0 mmol/1
tyramine in the reaction mixture.
The temperature dependence of monoamine oxidase
activity was determined under the established optimal
conditions, between 25 °C and 55 °C, using 58 U/g
protein enzyme activity. Using both substrates, max-
imum activity was obtained at 37 °C, which was es-
tablished as the optimal temperature for all further
assays (fig. 2).
Platelet monoamine oxid se was characterised as type
B with benzylamine as substrate, using two inhibitors
harmaline and pargyline. In this experiment, the
monoamine oxidase activity was 78 U/g. Under the
established optimal conditions, using 100 μτηοΐ/ΐ har-
maline or 10 μπιοΐ/ΐ pargiline, the resulting Line-
weaver-Burk plots gave K\ 24.6 μπιοΐ/ΐ and 7.04
μιηοΐ/ΐ, respectively (fig. 3).
Negative interference by catalase present in the sam-
ple was avoided by addition of 30 mmol/1 NaN3 (13).
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Fig. 1. Line\veaver-Burk plots for benzylamine (o —o, yx = 1.767x + 8.625, r = 0.999, Km = 0.204 mmoJ/1) and tyramine (o —o,
yx = 2.51 Ix + 8.803, r = 0.997, Km = 0.284 mmol/l) in 100 mmol/l TRIS-HC1 buffer, pH 7.6. The Michaelis plots are
inset. Conditions: for monoamine oxidase assay see "Procedure".
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Fig. 2. The effect of temperature on monoamine oxidase activ-
ity investigated'with benzylamine (o—o) and tyramine
(o-o) in 100 mmol/l TRIS-HC1 buffer, pH 7.6.
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Fig. 3. Double reciprocal plots for benzylamine oxidation by
human platelet monoamine oxidase in the presence of
100 μηιοΐ/ΐ harmaline (o —o), 10 μπιοΐ/ΐ pargyline
(Δ — Δ), and without inhibitor (o —o). Conditions: for
monoamine oxidase assay see "Procedure".
Analytical results
The linearity of the continuous monitoring ABTS
method was examined in the range of 0 to 83 U/g
platelet protein. Each sample was analysed in tripli-
cate. By regression analysis it was found that the
Lambert-Beer law was valid up to 83 U/g protein
(y = 91.625X - 1.510, r = 0.(998, Sy, x = 2.125). The
lowest catalytic activity of monoamine oxidase that
could still be assayed with good precision (CV
= 7.0%) was 6,9 U/g protein.
The precision of the ABTS method was examined
with three different samples, containing low, normal
and high monoamine oxidase activity, using benzyl-
amine and tyramine as substrates. All determinations
were repeated 10 times and calculated mean values,
standard deviations and coefficients of variation are
shown in table 1.
The accuracy of the proposed continuous monitoring
ABTS method was evaluated by comparison with the
end-point ABTS method originally established by
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Tab. 1. Precision of the continuous monitoring ABTS method
(n = 10) investigated by use of two substrates
Substrate
Benzylamine
Tyramine
(U/g)
11.7
33.9
72.4
8.9
28.8
60.5
SD
(U/g)
0.81
1.38
1.80
1.10
1.04
1.90
CV
(%)
6.9
4.1
2.5
12.1
3.4
3.1
Szulowicz et al. (8). Both methods were applied to 60
platelet samples. Monoamine oxidase activity ranged
from 15 to 97 U/g protein. An acceptable correlation
(y = 0.897x + 0.920, r = 0.983, Sy,x = 3.423) was ob-
tained (fig. 4). No significant difference up to 50 U/g
protein was obtained (p >0.01).
When the platelet monoamine oxidase activity was
greater than 60 U/g protein, the continuous monitor-
ing ABTS method gave results that were elevated by
about 10%.
Monoamine oxidase activity in normal and
pathological samples
Reference values for human platelet monoamine ox-
idase were determined using the new continuous mon-
itoring ABTS method on 67 healthy persons of both
sexes between 18 and 57 years of age. The statistical
parameters of the reference group were: χ = 33.2 U/g
protein, SD = 5.2 U/g protein, CV = 15.5%. The
lowest value in the reference group was 25 U/g protein
and the highest value was 42 U/g protein. In view of
the number of subjects in the reference group we
propose that these are the limits of the "normal"
range. The platelet monoamine oxidase activity does
not depend on sex or age.
Using the new continuous monitoring ABTS method,
platelet monoamine oxidase activities were deter-
mined in samples obtained from 76 patients with
chronic schizophrenia and 17 patients in acute phase
(fig- 5).
Both schizophrenic patient groups, chronic as well as
acute, had significantly lower platelet monoamine ox-
idase activity (p < 0.005) than control group. The
mean value of platelet monoamine oxidase activity in
the group of chronic patients was 29.2 U/g protein.
In the group with acute disease the mean value of
monoamine oxidase activity was 24.2 U/g protein.
This activity is significantly lower than in the control
group (p < 0.001). However, no statistically signifi-
cant difference between chronic and acute patient
groups was found (p > 0.05).
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Fig. 4. Correlation of results obtained by continuous monitor-
ing ABTS method (x) and end-point ABTS method (y)
in 60 different platelet samples: yx = 0.920 + 0.897x,
r = 0.983, Sy,x = 3.423.
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Fig. 5. Monoamine oxidase activities determined in platelets of
67 healthy persons (a), 76 chronic schizophrenic patients
(b) and 17 patients with acute disease (c).
Discussion
Monoamine oxidase is an intracellular enzyme, prin-
cipally found in all tissues and predominantly bound
to the inner mitochondrial membrane (14, 15). Many
methods for determination of monoamine oxidase
activity have been developed. Mostly they are time-
consuming, use radio-active labelled substrates, car-
cinogenic or unstable chromogens and are not prac-
ticable in routine work. For these reasons we propose
here a new spectrophotometric assay based on meas-
urement of the initial oxidation* rate of chromogen
ABTS. For the continuous monitoring ABTS method
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 7
Ivanovic and Majkic-Singh: Determination of platelet monoamine oxidase 451
benzylamine and tyramine were used as substrates.
The proposed continuous assay of monoamine oxi-
dase activity is simple, fast and takes advantages of
the high aqueous solubility and molar lineic absorb-
ance of ABTS (6, 7, 13). The rate of change in the
absorbance of the chromogen can be measured in a
low-cost visible range photometer. The investigation
presented here showed that the ABTS method is sen-
sitive, linear up to 83 U/g platelet protein and precise
(CV below 7.0% for substrate benzylamine). Good
correlation was obtained with the end-point ABTS
method (r = 0.983).
Many studies have been published on the reference
values of platelet monoamine oxidase activity. The
diversity of the methods make any comparison very
difficult. In any case we found no influence of age
and sex on monoamine oxidase activity, which is in
agreement with many other authors (9, 16, 17). How-
ever, Summers et al. (18) found statistically significant
differences between sexes, with a similar turnover
number for monoamine oxidase activity in platelets.
Platelet monoamine oxidase in psychiatric popula-
tions has been studied by many investigators. They
found that monoamine oxidase activity markedly de-
pends upon the psychiatric state, as well as genetic
and hormonal factors. Nies et al. (19) and Murphy &
Wyatt (20), using tryptamine as well as other sub-
strates, reported that platelet monoamine oxidase ac-
tivity was significantly lower in chronic schizophrenic
patients than in control subjects. Meltzner & Stahl
(21) pointed out the platelet monoamine oxidase ac-
tivity was lower in patients with acute schizophrenia
than in the control subjects, but only when tyramine
was used as substrate. Friedman et al. (22) found no
difference in monoamine oxidase activity between pa-
tients and normal control subjects, using tryptamine
as substrate. In contrast, Bailey et al. (23), Groshong
et al. (24) and Schildkraut et al. (25) did not find a
lower platelet monoamine oxidase activity in schizo-
phrenic patients using different substrates. Other au-
thors, such as Balmaker et al. (17), reported slightly
higher monoamine oxidase activity in schizophrenic
patients. As shown in figure 5, platelet monoamine
oxidase activity was significantly lower in chronic as
well as acute schizophrenic patients than in the control
group. Nevertheless, wide range of the results (from
12 to 52 U/g protein) indicate that many factors,
hormonal, dietary or genetic may influence the plate-
let monoamine oxidase level (19, 20, 26). However,
the presented data suggest the need for further clinical
investigation of the continuous monitoring ABTS
method, as a convenient laboratory test capable of
producing comparable interlaboratory results.
References
1. Fowler, C. J., Tipton, K. R, MacKay, A. V. P. & Youdim,
M. B. (1982) Neurosciehce 7, 1577-1594.
2. Oreland, R. & Shaskan, E. G. (1983) Trends Pharmacol.
Sei. 4, 339-341.
3. Sandler, M., Raveley, M. A. & Glover, V. (1981) J. Clin.
Pathol. 34, 292-302.
4. McEwen, C. M. Jr. (1956) J. Biol. Cherh. 240, 2003-2010.
5. Kochli, H. & von Wartburg, J. P. (1978) Anal. Biochem.
84, 127-135.
6. Majkic, N. & Berkes, I. (1977) Clin. Chim. Acta 80, 121-
131.
7. Ivanovic, D. I. & Majkic-Singh, N. (1986) Fresenius Z.
Anal. Chem. 324, 307.
8. Szutowicz, A., Kobes, R. D. & Orsulak, P. J. (1984) Anal.
Biochem. 138, 86-94.
9. Zeller, Ε. Α., Huprikar, S. V., Gibbons, R. D. & Millar, E.
(1984) Clin. Chim. Acta 737, 123-129.
10: Summers, K. M., Brown, G., K., Graig, I. W., Littlewood,
J., Peatfield, R., Glover, V., Rose, F. C. & Sandler, M.
(1982) Clin. Chim. Aota 121, 139-146.
11. Lowry, O. H., Rosebrough, N. J., Farf, A. L. & Randall,
R. J. (1951) J. Biol. Chem, 193, 265-275.
12. Bauer, E. L. (1971) Statistical Methods for Chemists, Ac-
ademic Press, pp. 71 -^93.
13. Majkic-Singh, N., Conteh, B., Stojanov, M. & Berkes, 1.
(1983) Enzyme 29, 120-125.
14. Blaschko; H., Richter, D. & Schlossmann, M. (1937)
Biochem. J. 31, 2187-2196.
15. Youdim, M. B. H. & Holzbauer, M. (1976) J. Neurol.
Transmission 38, 193-229.
16. Domino, E. F. & Khanna, S. S. (1976) Am. J. Psychiatry
133, 323-326.
17. Belmaker, R. HU Ebbesen, K., Ebstein, R. & Rimon, R.
(1976) Brit. J. Psychiat. 129, 227-232.
18. Summers, K. M., Andrew, B., Gillespie, C., Watt, D. C. &
Craig, I. W. (1985) Clin. Chim. Acta 752, 289-296.
19. Nies, Α., Robinson, D. S. & Harris, L. S. (1974) In: Ad-
vances in Biochemical Pharmacology (Usdin, E., ed.) Raven
Press (New York) Vol. /2, pp. 59-70.
20. Murphy, D. L. & Wyatt, R. J. (1972) Nature 238, 225-
226.
21. Meltzer, Η. Υ & Stahl, S. M. (1974) Res. Commun. Chem.
Pathol. Pharmacol. 7, 419-431.
22. Friedman, E., Shopsin, B. & Sathanthan, G. (1974) Am. J.
Psychiatry 757, 1392-1394.
23. Bailey, A. R., Crow, T. J. & Johnstone, E. C. (1975) Br. J.
Clin. Pharmacol. 2, 380-386.
24. Groshong, R. & Baidessarini, R. J. (1978) Arch. Gen.
Psychiatry 35, 1198-1205.
25. Schildkraut, J. J., Herzog, S. M. & Orsulak, P. J. (1976)
Am. J. Psychiatry 133, 438-440.
26. Youdim, M. B. H., Holzbauer, M. & Woods, H. F. (1974)
In: Advences in Biochemical Pharmacology (Usdin, E., ed.)
Raven Press (New York) Vol. 72, pp. 11 -28.
Prof. Dr N. Majkic-Singh
Department of Biochemistry
Faculty of Pharmacy
Dr Subotica 8, P.O. Box 146
YU-11000 Belgrade
J. Clin. Chem. Cito. Biochem. / Vol. 26, 1988 / No. 7

